D1 vs D2 Lymphadenectomy in Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective study with a propensity score-matched analysis in order to balance differences between patients with D1 and D2 lymphadenectomy for gastric cancer.The main aim is to analyse differences in the postoperative and oncological outcomes of patients with gastric cancer (GC) who underwent D1 and D2 gastrectomy.

Detailed Description
-----------------
In this propensity score-matched analysis of 128 patients, D2 lymphadenectomy improved long-term outcomes compared with D1 in patients with curative intent surgery for gastric cancer except for the group of patients older than 75 years and with early tumors.

Official Title
-----------------
Prognostic Implications of D1 vs D2 Lymphadenectomy in Gastric Cancer: a Propensity Score Matched Analysis

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Procedure: Lymphadenectomy type


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with GC stage I-III who underwent a curative gastrectomy +/- perioperative chemotherapy Exclusion Criteria: patients with adenocarcinoma Siewert type I/II, palliative surgery, R1/R2 resections and pathological stage (pStage) IV.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| D1 lymph node dissection (LND)<br>Patients with gastric cancer that underwent curative surgery with gastrectomy and D1 lymph node dissection | |
| D2 lymph node dissection (LND)<br>Patients with gastric cancer that underwent curative surgery with gastrectomy and D2 lymph node dissection | Procedure: Lymphadenectomy type<br>* D1 vs D2 lymph node dissection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival | Disease-free survival (DFS) was defined as the time from gastric surgery to the date of recurrence (locoregional, peritoneal recurrence and/or distant metastases). | percentage of patients without disease recurrence alive at 3 and 5 years after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival (OS) was defined as the time from the date of surgery to the date of death from any cause | percentage of patients alive at 3 and 5 years after surgery | 
| Postoperative morbidity | Surgical complications were defined as any deviation from the normal postoperative course within 90 days after surgery, both during the hospital stay or after discharge. | from the surgery up to 90 days after the surgery | 
| Postoperative mortality | Mortality through post-operative follow-up | from the surgery up to 90 days after the surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastric cancer, lymphadenectomy, outcomes